Oivi: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Oivi}} | ||
|name=Oivi | {{Infobox company | ||
| | | name = Oivi AS | ||
| | | org_number = 920032265 | ||
| | | founded = 2017-11-25 | ||
|funding= | | employees = 7 | ||
| | | address = Norway | ||
| industry = 62.200 – Computer consultancy activities | |||
| website = https://www.oivi.co | |||
| nht_category = Startup | |||
| description = Oivi develops a smart fundus camera for diabetic retinopathy screening. Enables early detection of diabetic retinopathy at point-of-care, reaching high-risk patients wherever they are located. Uses custom-built optics and robotics with AI. Addresses the global diabetes epidemic — 500M adults with diabetes, 1 in 3 develop diabetic retinopathy. | |||
| notes = No disclosed revenue or funding. 7 employees. Waitlist mode for product launch. International support from EU and India innovation leaders. | |||
| related_companies = [[Picterus]], [[Diagnostrix]], [[NordicDx]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Medical Devices, Diagnostics, Eye Health, AI | |||
| sources = https://www.oivi.co (Wayback Machine); https://data.brreg.no/enhetsregisteret/api/enheter/920032265 | |||
}} | }} | ||
== | == About == | ||
Oivi AS is a Norwegian medical technology company developing smart eye screening solutions. Founded in 2017 with 7 employees, the company focuses on enabling early detection of diabetic retinopathy. | |||
== | == Technology == | ||
== | === Oivi Fundus Camera === | ||
[[Category: | Oivi has developed a system combining: | ||
[[Category: | * Custom-built optics | ||
* Robotics | |||
* Artificial intelligence | |||
* Cloud connectivity | |||
The Oivi camera enables screening for diabetic retinopathy at the point of care — in primary care centres, diabetes clinics, pharmacies, or eye hospitals — rather than requiring referral to a specialist ophthalmologist. | |||
== Clinical Need == | |||
* 500 million adults worldwide suffer from diabetes | |||
* Projected 51% increase in diabetes by 2045 | |||
* 1 in 3 people with diabetes develop diabetic retinopathy | |||
* Diabetic retinopathy is a leading cause of preventable blindness | |||
* Early detection enables treatment before vision loss occurs | |||
== Value Proposition == | |||
* Early detection of diabetic retinopathy reduces preventable blindness | |||
* Point-of-care screening reaches high-risk patients in primary care settings | |||
* Rapid diagnosis shortens time-to-treatment | |||
* Reduces costs for patients and healthcare systems | |||
== Market Position == | |||
Oivi competes in the diabetic retinopathy screening market with companies including Remidio, EYENZA, and others. The company's approach using custom-built optics and robotics represents a hardware-intensive approach to AI-based screening. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Medical Devices]] | |||
[[Category:Diagnostics]] | |||
[[Category:Eye Health]] | |||
[[Category:AI]] | |||
Latest revision as of 20:32, 14 April 2026
About[edit]
Oivi AS is a Norwegian medical technology company developing smart eye screening solutions. Founded in 2017 with 7 employees, the company focuses on enabling early detection of diabetic retinopathy.
Technology[edit]
Oivi Fundus Camera[edit]
Oivi has developed a system combining:
- Custom-built optics
- Robotics
- Artificial intelligence
- Cloud connectivity
The Oivi camera enables screening for diabetic retinopathy at the point of care — in primary care centres, diabetes clinics, pharmacies, or eye hospitals — rather than requiring referral to a specialist ophthalmologist.
Clinical Need[edit]
- 500 million adults worldwide suffer from diabetes
- Projected 51% increase in diabetes by 2045
- 1 in 3 people with diabetes develop diabetic retinopathy
- Diabetic retinopathy is a leading cause of preventable blindness
- Early detection enables treatment before vision loss occurs
Value Proposition[edit]
- Early detection of diabetic retinopathy reduces preventable blindness
- Point-of-care screening reaches high-risk patients in primary care settings
- Rapid diagnosis shortens time-to-treatment
- Reduces costs for patients and healthcare systems
Market Position[edit]
Oivi competes in the diabetic retinopathy screening market with companies including Remidio, EYENZA, and others. The company's approach using custom-built optics and robotics represents a hardware-intensive approach to AI-based screening.